Calidi Biotherapeutics, Inc. (CLDI)

USD 0.42

(-15.34%)

Total Liabilities Summary of Calidi Biotherapeutics, Inc.

  • Calidi Biotherapeutics, Inc.'s latest annual total liabilities in 2023 was 18.25 Million USD , down -57.97% from previous year.
  • Calidi Biotherapeutics, Inc.'s latest quarterly total liabilities in 2024 Q2 was 18.18 Million USD , down -17.27% from previous quarter.
  • Calidi Biotherapeutics, Inc. reported annual total liabilities of 43.43 Million USD in 2022, up 164.03% from previous year.
  • Calidi Biotherapeutics, Inc. reported annual total liabilities of 16.45 Million USD in 2021, down -32.39% from previous year.
  • Calidi Biotherapeutics, Inc. reported quarterly total liabilities of 21.97 Million USD for 2024 Q1, up 20.4% from previous quarter.
  • Calidi Biotherapeutics, Inc. reported quarterly total liabilities of 18.25 Million USD for 2023 Q4, down -7.25% from previous quarter.

Annual Total Liabilities Chart of Calidi Biotherapeutics, Inc. (2023 - 2020)

Historical Annual Total Liabilities of Calidi Biotherapeutics, Inc. (2023 - 2020)

Year Total Liabilities Total Liabilities Growth
2023 18.25 Million USD -57.97%
2022 43.43 Million USD 164.03%
2021 16.45 Million USD -32.39%
2020 24.33 Million USD 0.0%

Peer Total Liabilities Comparison of Calidi Biotherapeutics, Inc.

Name Total Liabilities Total Liabilities Difference
AIM ImmunoTech Inc. 9.14 Million USD -99.563%
Ampio Pharmaceuticals, Inc. 2.37 Million USD -668.266%
Armata Pharmaceuticals, Inc. 142.02 Million USD 87.148%
Actinium Pharmaceuticals, Inc. 45.06 Million USD 59.495%
Azitra, Inc. 2.2 Million USD -728.846%
Can-Fite BioPharma Ltd. 3.74 Million USD -387.293%
Chromocell Therapeutics Corporation 6.54 Million USD -179.073%
CEL-SCI Corporation 17.31 Million USD -5.433%
iBio, Inc. 7.41 Million USD -146.343%
Lineage Cell Therapeutics, Inc. 38.99 Million USD 53.19%
MAIA Biotechnology, Inc. 7.08 Million USD -157.485%
Matinas BioPharma Holdings, Inc. 46.33 Million USD 60.602%
Navidea Biopharmaceuticals, Inc. 12.51 Million USD -45.858%
NovaBay Pharmaceuticals, Inc. 5.72 Million USD -219.126%
NanoViricides, Inc. 1.35 Million USD -1243.415%
Oragenics, Inc. 1.79 Million USD -915.137%
BiomX Inc. 55.07 Million USD 66.856%
BiomX Inc. 55.07 Million USD 66.856%
Protalix BioTherapeutics, Inc. 50.86 Million USD 64.113%
Palatin Technologies, Inc. 10.85 Million USD -68.181%
Scorpius Holdings, Inc. 22.74 Million USD 19.739%
Theriva Biologics, Inc. 20.51 Million USD 11.017%